Search results
1,126 results
-
Daewoong Pharmaceutical Supplies AI Monitoring System to Ajou University Hospital 대웅제약이 아주대학교병원에 인공지능(AI) 스마트 병상 모니터링 시스템 '씽크(thynC)'를 공급하며 경기남부권 상급종합병원의 디지털 전환을 지원한다. 대웅제약은 26일 아주대병원 총 7개 병동 342병상에서 씽크를 본격 운영한다고 밝혔다. 아주대병원은 향후 적용 병동을 순차적으로 늘려 최대 1100병상까지 확대할 계획이다. 중증·응급환자 진료를 담당하는 상급종합병원은 환자 상태 변화를 신속히 파악하는 것이 중요하다. 특히 일반병동은 중환자실과 달리 의료진이 환자를 지속적으로 관찰하기 어려워, 실시간 모니터링을 통해 이상 징후를 조기에 발견하는 효과가 기대된다. 씽크는 환자가 착용하는 웨어러블 바이오센서를 통해 심전도, 심박수, 맥박수, 호흡수, 산소포화도 등 주요 생체신호를 실시간으로 측정한다. AI 기반 낙상 및 응급 부정맥 감지·분류 기능도 제공해 의료진의 신속한 대응을 돕는다. 환자에게 이상 징후가 감지되면 병동 모니터링 화면에 알람이 표시된다. 측정된 생체정보는 전자의무기록(EMR)과 연동돼 60초 간격으로 최신 수치가 자동 기록된다. 아주대병원은 지난해 장비 도입과 기반시설 구축을 시작했고, 올해 8월까지 임상 현장에 맞춘 최적화 작업을 진행했다. 이후 9월부터 흉부외과와 순환기내과 병동을 중심으로 운영을 확대했으며, 이달에는 응급병동과 간호·간병통합서비스 병동 등으로 적용 범위를 넓혔다. 대웅제약은 상급종합병원과 주요 거점병원을 중심으로 중증·응급환자 관리에 필요한 스마트병동 구축을 확대하고 있다. 씽크는 이달 기준 전국 218개 의료기관, 누적 2만54병상에 도입됐다. 회사는 의료기관별 환자 특성과 운영 환경을 고려한 활용 가이드를 마련해 다양한 진료 현장에서 씽크가 효과적으로 활용되도록 지원할 방침이다. 한상욱 아주대학교 의료원장은 "입원환자의 주요 생체신호를 실시간으로 확인하고 이상징후를 조기에 발견할 수 있어 환자 안전을 한층 강화할 것으로 기대한다"고 말했다. 이창재 대웅제약 대표는 "아주대병원과의 협력을 강화하고 경기남부권 의료기관의 디지털 전환과 환자 중심 진료환경 조성을 지원하겠다"고 말했다. 한편, 대웅제약은 경기 화성시 향남 대웅바이오 3공장에 차세대 약물전달 기술인 마이크로니들(Microneedle) 제조 인프라를 구축한다. 내년 상반기까지 3공장 내 마이크로니들 전용 무균 임상의약품 제조소의 GMP 승인을 완료해 안정적인 임상의약품 공급과 상업화 기반 마련에 나선다는 계획이다.* This article has been translated by AI. October 26, 2026 11 -
62 Companies Submit Plans to Improve Low PBR Ahead of Disclosure Deadline ◆Aju Economy Major News▷62 companies submit plans to improve low PBR; effectiveness remains uncertain- As the disclosure of companies with low price-to-book ratios (PBR) approaches, a total of 62 listed companies have submitted improvement plans by the deadline of October 22, including 34 from the KOSPI and 28 from the KOSDAQ.- On the deadline day alone, 46 companies made their announcements, accounting for 74.2% of all submissions, while financial authorities plan to publicly disclose the list of low PBR companies on November 2.- Companies that submit plans detailing the causes of their undervaluation, improvement goals, and execution strategies can be exempt from the public disclosure for one year, provided they meet the disclosure requirements. However, companies that have been in a low PBR state for six consecutive years are excluded from this exemption.- Concerns have been raised that the burden of continuous evaluation of performance, dividends, and share buyback policies, along with the reputational risks associated with being on the list, may limit voluntary participation from companies.- The financial investment sector has questioned the effectiveness of voluntary disclosures that lack legal enforcement and sanctions, while also expressing concerns that defining low PBR as a problem without considering individual company conditions, such as market conditions and business structure, is inappropriate.◆Major Reports▷Emerging Market Equity Funds See Largest Weekly Inflow in 52 Weeks [Yuanta Securities]- During the week of October 15-21, global equity funds recorded a net inflow of $55.56 billion, continuing a significant influx for the second consecutive week. Notably, emerging market funds saw a net inflow of $33.5 billion, the highest in 52 weeks, surpassing developed markets.- Investment funds shifted from a U.S. focus to Asian semiconductor stocks, with developed market funds experiencing the largest net inflow in technology stocks in 18 weeks, while defensive sectors like consumer goods and utilities faced the largest net outflow in 52 weeks.- By theme, leveraged funds recorded their largest net inflow in 52 weeks, while large mixed funds maintained net inflows, contrasting with significant net outflows from small mixed funds.- Among emerging markets, capital inflows expanded into Asian markets, including China and Taiwan, with South Korean equity funds also seeing a net inflow rate of 3.22%, the highest in 14 weeks, making it the only country among major Asian nations to experience simultaneous inflows from both offshore and domestic sources.- This influx is attributed to bargain-hunting following a sharp decline in Asian markets due to U.S. inflation indicators and credit concerns related to AI companies. Future inflows will likely depend on the upcoming Federal Open Market Committee (FOMC) meeting and the performance and shareholder return policies of major semiconductor companies.◆Major Disclosures After Market Close (October 23)▷Asiana Airlines lawsuit verdict and decision (claims above a certain amount)▷Daegu Department Store (revised) decision on asset transfer▷BioInfra extension of short-selling restrictions (extension of short-selling ban)▷Seohan extension of short-selling restrictions (extension of short-selling ban)◆Fund Trends (as of October 22, excluding ETFs)▷Domestic equity: -59.8 billion won▷Overseas equity: -11.2 billion won◆Key Schedule for Today (October 26)▷Oracle AI World (until October 28)▷IBM TechXchange 2026 (until October 29)▷OpenAI DevDay Exchange* This article has been translated by AI. October 26, 2026 08
-
Big Tech Enters AI Drug Development, South Korean Pharma Companies Join the Race Artificial intelligence (AI) is set to accelerate the expansion of drug development as global tech giants enter the field. In this context, South Korean pharmaceutical and biotech companies are also increasingly engaging in AI-driven drug development.According to industry sources, OpenAI has recently acquired the drug development management platform company Orchestra Bio, marking a significant step into the life sciences sector. Orchestra Bio has developed an AI platform that manages research schedules and progress during the drug development process, coordinating tasks between internal teams and external partners. OpenAI plans to integrate this technology and workforce with its life sciences research AI, Rosalind. This signifies a shift for AI, which has primarily been used for candidate substance discovery, to now encompass development timelines and decision-making management.Industry experts believe that the entry of big tech into the life sciences market will drive growth in the AI drug development sector. As services expand from general AI research support to comprehensive management of the entire development process, the demand for AI adoption among pharmaceutical companies is expected to rise.South Korean pharmaceutical firms are also applying AI in drug development. LG Chem is focusing on using AI to identify patients who are likely to respond well to treatments. On October 20, LGs AI Research Institute and the U.S. biotech venture capital firm Flagship Pioneering held the LG AI Bio Conference, unveiling a strategy to refine clinical trial patient selection based on biomarkers. The goal is to develop a personalized mRNA cancer vaccine that predicts neoantigens for individual patients, with preclinical trials set for next year and clinical entry aimed for 2029.SK Biopharm secured computational resources equivalent to 128 NVIDIA AI accelerators, known as B200, last month, intending to use them for translational research that bridges non-clinical study results to clinical development. They are utilizing cloud subscription services from SK Telecoms data center. The plan is to enhance the accuracy of candidate substance evaluation and development decision-making through integrated analysis of disease, target, and compound data.Among AI biotech firms, Galax is gaining attention for its technology that designs proteins from scratch using AI. Galax is conducting joint research with global pharmaceutical companies such as Boehringer Ingelheim and AstraZeneca, as well as collaborating with domestic firms like LG Chem, Celltrion, and Dong-A ST. In February of this year, Galax raised 42 billion won in a Series B funding round, bringing its total investment to 68 billion won.The government is also stepping in to provide support. The Korea Pharmaceutical and Bio Associations K-MELLODDY project is set to establish a collaborative learning platform worth 34.8 billion won from 2024 to 2028. This platform will allow pharmaceutical companies to share AI algorithms without disclosing proprietary drug development data, aiming to create models that predict drug toxicity and metabolism.Industry insiders believe that ultimately, data will determine competitiveness. While general AI can be accessed through big tech services, creating differentiated models requires accumulating disease-specific non-clinical and clinical data. An industry representative stated, It is crucial to demonstrate the actual figures showing reduced development timelines and improved clinical success rates due to AI adoption. October 25, 2026 19
-
Surge in Foreign Tourist Pharmacy Spending Boosts Sales for Pharmaceutical Companies Foreign tourists are increasingly adding pharmacies to their shopping itineraries, expanding beyond popular spots like Olive Young and Daiso. The rise in visitors seeking skin treatments in South Korea has led to a growing demand for post-treatment ointments and creams purchased at pharmacies.According to a report released by BC Card on October 25, 2026, foreign medical spending in South Korea surged by 98% in the first half of this year compared to the same period last year. Notably, pharmacy spending skyrocketed by 1,176.9% during the same timeframe.As the K-beauty trend attracts more foreign tourists, their spending is shifting from beauty retail channels to specialized outlets like dermatology clinics and pharmacies.The most sought-after products among foreign tourists at pharmacies include acne and scar ointments, regenerative creams, and cosmetics containing PDRN. Domestic pharmaceutical companies are responding by expanding their pharmacy-exclusive product lines.PharmaResearch, known for its skin booster Rejuran, is increasing its presence in the pharmacy market. According to its subsidiary, PharmaResearchMedicare, the pharmacy supply of the Rejuvi brand grew by approximately 30% in the second quarter compared to the first quarter.Rejuvi Neck Cream is the first PDRN topical agent in South Korea, having been sold in pharmacies for over a decade, gaining significant recognition. As pharmacies emerge as a new beauty and wellness shopping channel, PharmaResearchMedicare continues to see growth in its Rejuvi brand focused on pharmacy channels.The distribution scale of Rejuvi-S in pharmacies is also expanding. This product is an ampoule with a high concentration of PharmaResearchs cosmetic ingredient c-PDRN, which helps soothe the skin and improve turnover.According to the company, demand has consistently increased since its launch in November last year, with pharmacy shipments in May this year reaching approximately 41 times (4,168%) the initial launch volume.A representative from PharmaResearchMedicare stated, We will respond to a wide range of care needs, from daily home care to post-treatment care, through various categories of products including cosmetics, pharmaceuticals, medical devices, and inner beauty. October 25, 2026 13
-
Hanmi Pharmaceutical Names Next-Generation Obesity Drug 'Zantrutide' Following WHO Registration Hanmi Pharmaceutical has finalized the name for its next-generation obesity drug. On October 23, the company announced that the international nonproprietary name (INN) for its triple-action obesity drug candidate, HM15275, has been registered as zantrutide with the World Health Organization (WHO). The WHO manages international nonproprietary names to standardize drug ingredient names and prevent confusion. According to the company, the name zantrutide combines the prefix zan, symbolizing best and balance, tru, meaning triple, and tide, referring to peptides. Zantrutide is a next-generation triple-action drug that simultaneously targets three receptors: GLP-1 (glucagon-like peptide-1), GIP (gastric inhibitory polypeptide), and glucagon, which are involved in appetite regulation. Hanmi Pharmaceutical aims to demonstrate a weight loss effect of over 25%, a result previously achievable only through gastric bypass surgery, while also minimizing muscle loss during development. Currently, zantrutide is undergoing Phase 2 clinical trials in the United States for patients with obesity and diabetes. The Phase 2 trial for obesity patients is expected to conclude in the first half of next year. Choi In-young, Vice President and Head of Future Growth at Hanmi Pharmaceutical, stated, Hanmis promising research and development asset has secured a globally recognized name. The official registration of zantrutides international nonproprietary name is significant in enhancing its future value and recognition as a global new drug asset. Meanwhile, Hanmis obesity treatment Epe (active ingredient epeglanatide) will begin prescriptions at select medical institutions starting on the 29th. This comes just 22 days after receiving approval from the Ministry of Food and Drug Safety on October 7. Epe is the first domestically produced GLP-1 obesity treatment and the 45th domestic new drug. According to Hanmi Pharmaceutical, Epe has shown an average weight loss effect of around 10% after 40 weeks of self-administration once a week. The supply price for the first months dosage is approximately 130,000 won, which is lower than Eli Lillys Mounjaro at around 270,000 won for the lowest dosage over four weeks and Novo Nordisks Wegovy priced in the low 200,000 won range.* This article has been translated by AI. October 25, 2026 12
-
Korea's Startup Agency Supports 10 Companies Entering Japanese Market The Korea Small and Medium Enterprises and Startups Agency announced on October 23 that it is operating the 2026 Global Startup School Local Entry Program (G-Camp) in Japan from October 19 to 30 to support promising startups entering the Japanese market. G-Camp is a program designed to assist companies enrolled in the Global Startup School with their overseas expansion, providing support for product and service localization, market fit verification, and local network establishment. The agency has previously operated G-Camp programs primarily in Europe, Southeast Asia, and the Middle East, launching its first program in France in 2024. This year, it established a Japan Track for the first time in response to the demand from enrolled companies for entry into Japan. Participating companies have enhanced their understanding of the Japanese business environment and market characteristics through the first and second G-Camp sessions. They focused on improving their competitiveness for practical entry by developing investment attraction presentations (IR) and sales decks tailored to local investors and buyers, in collaboration with industry mentors. The third G-Camp includes ten startups from various fields, such as interactive AI avatar solutions, K-beauty brands based on bio R&D, AI-driven neuroscience sleep solutions, and AI clinical solutions for pet healthcare. These companies participated in the Japan Summit, a global open innovation event held on October 21-22, seeking collaboration opportunities with local businesses. The event featured over 100 major corporate partners, including MUFG, Aisin, Asahi Group, and Shimadzu, along with more than 70 global startups and approximately 2,500 local attendees. Domestic startups showcased their products, technologies, and services at dedicated booths and presented their innovative technologies and business models on an official pitching stage. The agency will continue to support one-on-one business meetings and buyer matching with local investors and partners during the remaining camp period. Im Ji-hyun, head of the Youth Startup School at the agency, stated, The Japan Summit provided an opportunity for promising startups preparing to enter Japan to confirm their competitiveness in the local market based on their excellent technology and business potential. We will support the participating companies in their entry into the Japanese market and the creation of tangible business results.* This article has been translated by AI. October 23, 2026 12
-
Korean Wild Kiwi Gains Traction as New Income Source for Forestry Workers Research is intensifying to develop the Korean wild kiwi as a high-value industrial resource. The initiative aims to secure a new income source for local forestry workers by linking production with functional material development, fermentation, processing, and distribution.The Jeonnam Gwangju Forest Research Institute held a field discussion on October 21, attended by over 40 participants, including experts from the National Institute of Forest Science, forestry workers, local government officials, and academia.The discussion focused on establishing a stable production base for the wild kiwi and addressing challenges in cultivation while reflecting industry demands in research and development.The wild kiwi is a climbing plant native to Korea, belonging to the same genus as the common kiwi. Its fruit has no fuzz, making it edible with the skin, and it has a sweet and tangy flavor, suitable for fresh consumption as well as various processed products like beverages and fermented foods.The potential for the wild kiwi to become a new income crop for forestry workers is particularly noteworthy if suitable varieties are secured and cultivation techniques are standardized.During the discussion, research findings covering the entire production and distribution process were shared, from variety development to post-harvest quality management and the use of functional materials for industrialization.Kim Cheol-woo, a researcher at the National Institute of Forest Science, introduced the current status of domestic kiwi variety development and its applications, while Eo Hyun-ji presented strategies for improving distribution quality through post-harvest management techniques.Yang Cheon, a researcher at the Jeonnam Gwangju Forest Research Institute, explained the status of securing genetic resources for the wild kiwi and the direction of ongoing research and development.Professor Heo Ho-jin from Gyeongsang National University discussed research on the brain health benefits of kiwi extracts, and Kim Gyeong-je from the Jangheung Mycology Bio Center presented findings on the fermentation process and industrial materialization of the wild kiwi.Kang Nam-gil, CEO of AFGM Consulting, proposed strategies for securing demand and commercialization of fermented kiwi, outlining ways to connect research outcomes to actual industry applications.Participants engaged in a Q&A session to discuss challenges in the industrialization process, including cultivation characteristics by variety, improving productivity, ensuring stable raw material supply, maintaining post-harvest quality, and developing processed products and securing sales channels.There was a consensus that for the wild kiwi to become a viable income source for forestry workers, it is essential to establish a production system that can continuously supply raw materials of consistent quality, alongside the dissemination of cultivation techniques and a solid processing and distribution foundation.Following the discussion, participants tasted kiwi processed products and toured the research institutes test plots, observing the growth characteristics and cultivation status of different varieties firsthand.The Jeonnam Gwangju Forest Research Institute has been selected for the Forest Services 2026 Green Bio Future Value Chain Technology Development (R&D) project, with an 80 million won budget this year to conduct research on forest resources that respond to industrial demand, utilizing wild kiwi and red pine.The research focuses on securing superior genetic resources, standardizing propagation and nursery techniques, enhancing AI-based growth and environmental data analysis, and advancing smart nursery technology.Through this, the institute aims to establish a stable raw material production system and provide a technical foundation to meet the quality and quantity demands of the industry.The Forest Research Institute plans to incorporate the cultivation technology improvement requests raised in the field and industry demands into its research and development, expanding the dissemination of applicable technologies for forestry workers and linking them to industrialization.Oh Deuk-sil, director of the Jeonnam Gwangju Forest Research Institute, stated, This discussion was a meaningful opportunity to explore the industrialization potential of the wild kiwi, from cultivation techniques to processing and functional material utilization. We will strive to ensure that the wild kiwi becomes a new income resource for local forestry workers through research and development that reflects field demands and the dissemination of cultivation techniques.The success of wild kiwi industrialization hinges on how effectively research outcomes can be integrated into actual cultivation and processing industries. Key future challenges include securing stable production volumes, ensuring quality uniformity, and validating the market competitiveness of processed products.Meanwhile, the Jeonnam Gwangju Forest Research Institute is conducting research to enhance the industrial value of wild kiwi and red pine, based on this years 80 million won research and development budget. The goal is to systematize the production base from securing superior genetic resources to developing smart nursery technology, thereby linking the high-value utilization of local forest resources to increased forestry income.* This article has been translated by AI. October 23, 2026 08
-
5 Billion Won Investment in Gokseong Rose Industry to Boost Bioeconomy A private investment initiative is underway to expand the rose industry in Gokseong, Jeollanam-do, into high-value sectors such as cosmetics. The goal is to transition roses from mere tourism and ornamental resources to a specialized regional industry through research and product development. On October 21, the Jeollanam-do Bio Industry Promotion Agency announced that it signed a 500 million won investment attraction agreement and a joint research and development memorandum of understanding (MOU) with Molligarden to revitalize the Gokseong rose industry and enhance the competitiveness of the green bioindustry. Under this agreement, Molligarden plans to invest a total of 500 million won in phases from 2027 to 2031 to establish infrastructure for the rose-related industry, implement cultivation techniques suitable for the local environment, and develop products. The Jeollanam-do Bio Industry Promotion Agency will support companies in research and development and establish a cooperative system for developing high-value products using roses. This agreement aims to increase the added value of the agricultural and life sciences industry by utilizing Gokseongs specialized rose resources and securing sustainable cultivation techniques to respond to climate change. The focus is on strengthening the technical foundation necessary for rose cultivation while creating an industrial ecosystem that connects raw material production, product development, and commercialization. Molligarden, a tenant at the Jeollanam-do Bio Industry Promotion Agencys Green Bio Headquarters Eco-Friendly Center, develops and manufactures products such as cosmetics and soaps made from roses. The company plans to accelerate research and development and commercialization to expand the utilization of rose raw materials and enhance product competitiveness through this agreement. Both organizations will collaborate on advancing rose cultivation and raw material utilization technologies, researching climate change responses, and developing rose-based cosmetics. Additionally, they aim to enhance the stability of rose production through the implementation of cultivation techniques suitable for the local environment and to identify follow-up cooperative projects that can translate research and development outcomes into actual product production and sales. The Jeollanam-do Bio Industry Promotion Agency has been working to expand research infrastructure to support technology development and commercialization for tenant companies at the Eco-Friendly Center. This agreement is significant as it combines the technological support of a public research institution with the product development capabilities of a private company. As Gokseong County seeks to host a garden expo, expanding the foundation of the rose-related industry is expected to enhance the industrial utilization potential of tourism resources. However, the 500 million won investment is planned to be executed in phases over the next five years, and the actual investment execution and facility construction results will need to be confirmed during the project implementation process. Seo Hyung-bin, head of the Jeollanam-do Bio Industry Promotion Agency, stated, This agreement will enhance the growth potential of the regions specialized industry utilizing Gokseongs rose resources and create opportunities for research institutions and tenant companies to achieve industrial outcomes. We will continue to actively support companies in research and development and commercialization to strengthen the competitiveness of the regional agricultural and life sciences industry. Kim Kyung-won, CEO of Molligarden, said, We will enhance the competitiveness of rose-based products and develop into a company that grows together with the region through continuous technology development and investment. For this agreement to lead to the actual growth of the local rose industry, it will be essential to implement the planned investments, apply cultivation techniques in the field, commercialize products, and secure stable sales channels. Meanwhile, the Eco-Friendly Center at the Jeollanam-do Bio Industry Promotion Agencys Green Bio Headquarters supports the industrial utilization of local agricultural and life science resources and the research and commercialization of tenant companies. Through this agreement with Molligarden, it plans to promote cooperative projects aimed at enhancing the value of Gokseongs rose resources and establishing related industrial infrastructure.* This article has been translated by AI. October 22, 2026 19
-
Irum Bio CEO Jo Jin-hyung Donates 3 Million Won to Muan County Jo Jin-hyung, CEO of Irum Bio, has continued his contributions to the community by donating 1 million won to Muan County as part of the hometown love donation program. Since his first donation in 2023, he has contributed a total of 3 million won over three occasions.Muan County announced on the 21st that Jo Jin-hyung participated in the hometown love donation program by donating 1 million won.Jo first connected with Muan Countys relay donation initiative when the program was launched in 2023. He has shown ongoing interest in the region by participating in donations again in 2025 and this year.This donation is particularly significant as it reflects a commitment to sustained support rather than a one-time contribution.Jo stated, “I participated in the hometown love donation to convey my warm support for the development of Muan County. I will continue to pay attention to Muan County and share positive influence.”Mayor Kim San expressed gratitude to Jo for his consistent interest and contributions to Muan County, stating, “The donated funds will be used wisely to enhance the local economy and improve the welfare of residents.”Muan County plans to utilize the funds generated through the hometown love donation program for the welfare of local residents and necessary community projects.Meanwhile, the hometown love donation program allows individuals to donate to local governments outside their registered addresses, with donors eligible for tax deductions and rewards as per relevant laws. Local governments use the donations to create hometown love funds for projects aimed at enhancing residents welfare.* This article has been translated by AI. October 22, 2026 17
-
Regenerative medicine firm soars above IPO price on KOSDAQ debut SEOUL, October 22 (AJP) - Regenerative medicine firm MS Bio more than doubled from its initial public offering (IPO) price on its KOSDAQ debut Thursday before paring gains later in the day. The stock climbed as high as 19,650 won (US$14.81), about 2.5 times its IPO price of 7,800 won. It was trading at 12,920 won as of around 5 p.m. in after-hours trading, up 65.64 percent from the offering price. The firm priced its shares at the top of its proposed range of 6,800 won to 7,800 won after institutional investors submitted bids exceeding the shares available by 1,096.56 times. The IPO drew 2,269 institutional investors during the book-building process. Retail demand was also strong, with subscriptions oversubscribed 1,538.51 times and investors placing approximately 6.02 trillion won in deposits for share allocations. KB Securities served as the lead underwriter for the 31.2 billion won offering. Founded in 2015, MS Bio develops and manufactures medical products using donated human tissue and biomaterials to help repair and regenerate damaged skin, bone and other tissues. It posted revenue of 23.79 billion won and operating profit of 8.56 billion won in 2025. The firm plans to use proceeds from its IPO to build a new manufacturing facility in Ochang, North Chungcheong Province, increase production capacity and expand into overseas markets including Viet Nam and the U.S. October 22, 2026 17 -
Boryung Reports 3rd Quarter Operating Profit of 69.4 Billion Won, Surpassing Last Year's Annual Results Boryung has surpassed last years annual operating profit in just three quarters this year. The company announced on October 22 that it achieved consolidated sales of 314.4 billion won and an operating profit of 25.5 billion won for the third quarter. During the same period, it recorded a net loss of 13.2 billion won. Sales for the quarter increased by 12.3% compared to the same period last year. However, operating profit decreased by 13.4%, and the company shifted to a net loss. Cumulative sales reached 849.3 billion won, with cumulative operating profit at 69.4 billion won and cumulative net profit at 52.3 billion won, marking increases of 10%, 5.7%, and 21.1%, respectively, compared to the previous year. The operating profit margin stood at 8.2%. Growth in sales was driven by increased prescriptions for the hypertension treatment Canab family, joint sales of the dyslipidemia treatment Atoget, and revenues from the cancer drug Taxotere. According to market research firm Ubist, prescriptions for the Canab family in the third quarter rose by 7.1% compared to the same period last year, outpacing the growth rate of the hypertension treatment market at 4.2%. Canabjet, launched in June, surpassed 1 billion won in monthly prescriptions by September, achieving the fastest record among Canab family products within just four months. As of September, it held a 56% market share in the three-drug combination market. The oncology sector also showed growth. Taxotere recorded global sales of 21.3 billion won and domestic sales of 6.4 billion won, totaling 27.7 billion won in the third quarter, reflecting the first full three-month sales since its acquisition. Cumulative sales in the oncology sector for the third quarter reached 221.4 billion won, an increase of approximately 24% compared to the previous year. The cumulative gross profit margin was recorded at 41.4%. A Boryung official stated, We expect the profitability of the oncology sector to continue improving through a phased strategy involving production conversion and formulation enhancements.* This article has been translated by AI. October 22, 2026 14
-
Kolon Biotech to Showcase CDMO Capabilities at BIX 2026 Kolon Biotech, a subsidiary of Kolon Life Science, is set to expand its global partnerships by showcasing its capabilities in contract development and manufacturing organization (CDMO) for cell and gene therapies.The company announced it will participate in the BioPlus-Interphex Korea 2026 (BIX 2026) event, taking place from October 28 to 30 at Seoul COEX. During the event, Kolon Biotech will operate an independent booth in the CMO/CDMO zone, where it will introduce its CDMO services for advanced biopharmaceuticals, including cell therapies, genetically modified cell therapies, stem cell therapies, and exosome therapies. The company plans to hold business meetings with domestic and international biotech firms to explore new partnerships and collaboration opportunities.Founded in 2020 as a specialized CDMO for cell and gene therapies, Kolon Biotech was established by spinning off the bio-manufacturing division of Kolon Life Science. The company operates a Good Manufacturing Practice (GMP) facility in Chungju, capable of producing both clinical trial materials and commercial products.Kolon Biotech offers a comprehensive range of services throughout the drug development process, including process development, quality testing, GMP production, regulatory support, and storage and transportation. The Chungju Bio Plant 1 is responsible for clinical trial samples and initial commercial supply, while Bio Plant 2 handles large-scale commercial supply.To ensure stable mass production of cells, the company is also focusing on expanding the use of automated systems and closed systems in its two-dimensional (2D) cell culture processes. This initiative aims to enhance productivity and strengthen cost competitiveness in manufacturing.A representative from Kolon Biotech stated, At BIX 2026, we will showcase our CDMO capabilities and seek new collaboration opportunities. We aim to continuously enhance our competitiveness as a professional and flexible CDMO partner that reliably supports our clients from drug candidate development to commercial production.* This article has been translated by AI. October 22, 2026 10
-
Pharmaresearch Strengthens Academic Marketing with 'Rejuran' Pharmaresearch is enhancing its academic marketing for its flagship product, Rejuran, focusing on its aesthetic product line. The strategy aims to broaden lectures and academic exchanges for medical professionals to communicate the scientific basis and clinical applicability of its products. On October 22, Pharmaresearch announced that it is strengthening academic activities related to its key aesthetic products, including Rejuran, Evercle, and Rejuderma. The company plans to share scientific principles and clinical experiences for each product to improve medical professionals understanding and discuss clinical considerations and applications based on treatment objectives. The company participated in the Korean Obesity and Aesthetic Medicine Society (KOAT) academic event and the Korean Functional Aesthetic Medicine Society (KFCC) fall academic conference on October 18, where it conducted lectures related to its major products. At the KOAT event, clinical experiences with Rejuran and Evercle were shared. Lee Kyung-hwan, a project director at the clinic and a cooperating director of KOAT, delivered a lecture titled The Evolution of Skin Rejuvenation: Designing Synergy Protocols with DOT PN and PLLA. PN (polynucleotide) is a polymer derived from DNA used in skin aesthetic procedures, while PLLA (poly-L-lactic acid) is a biodegradable polymer that induces collagen production in aesthetic treatments. Rejuran is based on PN, and Evercle is based on PLLA. At the KFCC fall academic conference held the same day, lectures continued on the scientific principles and clinical applications of Rejuran, Evercle, and Rejuderma. Kim Michael, executive director of medical strategy at Pharmaresearch, presented on the scaffold structure of Rejurans DOT polynucleotide and its structural differences from PDRN (polydeoxyribonucleotide). Park Hyun-jun, director of Meilin Clinic, introduced the aesthetic and functional medical value of Evercle and its clinical applications. Hwang Won-wook, director of Cheongdam Revelle Clinic, explained the functional medical approach to skin barrier damage and the recovery mechanisms through Rejuderma. Park Kyung-min, director of Seongsu Melting Clinic, discussed strategies for preserving lean body mass during GLP-1 treatment, presenting a functional medical approach using placental extracts. A Pharmaresearch representative stated, We were able to deeply convey the excellence and clinical value of our regenerative medicine-based aesthetic portfolio to medical professionals. We will continue to expand academic exchanges to share various experiences and cases from clinical practice.* This article has been translated by AI. October 22, 2026 10
-
Jeon Byeong-seo Calls for Exit Mechanism in Policy Finance at Beijing Forum Jeon Byeong-seo, head of the China Economic and Financial Research Institute, acknowledged the necessity of policy finance to support Chinas strategic industries such as semiconductors and artificial intelligence. However, he emphasized the need to establish a clear exit mechanism regarding the timing of support termination and the transition to private funding.Speaking at the 2026 Financial Forum held in Beijing on October 21, Jeon shared insights from South Koreas financial experiences with Chinese financial professionals. He highlighted exit, order, and patience as three key concepts, which garnered significant attention at the forum.Jeon likened finance to the blood of the economy, stating, What matters is not the amount of blood but the blood pressure and circulation. He explained that if finance outpaces the real economy, bubbles can form, while lagging behind can stifle growth, making it crucial for finance and the real economy to maintain balance.His first recommendation was the establishment of an exit mechanism for policy finance. He noted that South Korea utilized banks as tools for industrial policy from the 1960s to the 1980s, providing low-interest funds primarily to the steel, shipbuilding, automotive, and electronics sectors. This strategy helped South Korea emerge as a manufacturing powerhouse, but it also led to weakened risk assessments by banks and a belief among companies in their invincibility, resulting in adverse effects.Jeon pointed out that just before the 1997 financial crisis, the debt ratio of South Korean manufacturing firms approached 400%, and after the crisis, 168 trillion won in public funds was injected to rebuild the financial system. He stressed that while policy finance for strategic industries is necessary, it is essential to determine in advance when support will end and when private funding will take over. Otherwise, policy finance could devolve into a life support system for uncompetitive companies.The second point Jeon emphasized was order. He reflected on the launch of the KOSDAQ market in 1996, which became a growth foundation for bio-pharmaceutical, gaming, and battery companies. However, he noted that South Korea made the mistake of opening the market before strengthening regulations. This led to widespread poor listings and unfair trading, causing the KOSDAQ index to plummet by 80% in a single year in 2000, taking over a decade to restore market confidence. He advised that the Chinese equivalent of NASDAQ, the STAR Market, should not only lower listing thresholds but also strengthen exit mechanisms. He argued that three fundamental systems—information disclosure, delisting, and penalties for illegal activities—must be properly established before expanding the market.Lastly, Jeon highlighted the importance of nurturing long-term investors, referred to as patient capital. He noted that individual investors dominate the South Korean stock market, which has experienced volatility this year due to leverage and forced liquidations. In contrast, long-term institutional investors like the National Pension Service can act as a buffer against market fluctuations. He urged that China, with the worlds largest household savings, should transition funds from real estate and deposits into long-term investments through pensions, insurance, and public funds. He stressed that for long-term capital to flow in, not only should investments be smooth, but recovery channels must also be expanded, including mergers and acquisitions (M&A) and secondary funds (S funds).Jeon also proposed expanding financial cooperation between South Korea and China. Given the close ties in semiconductor and battery supply chains, he argued that collaboration should deepen in areas such as science and technology finance, direct trading of the yuan and won, and financial safety nets.The Financial Forum is an international financial forum co-hosted by Chinas major financial policy authorities and the Beijing municipal government. The 2026 event took place from October 19 to 22 at the Beijing Financial Street, focusing on Openness, Cooperation, Inclusion: Building a New Ecosystem for Global Financial Development, with over 400 key figures from more than 40 countries and regions in attendance.* This article has been translated by AI. October 22, 2026 10
-
Bukwang Pharmaceutical Collaborates on Digital Treatment for Schizophrenia Bukwang Pharmaceutical is partnering with Samsung Medical Center and mental wellness startup Bluesignum to develop a digital treatment aimed at improving social cognitive function in patients with schizophrenia. The collaboration seeks to combine the pharmaceutical companys expertise in central nervous system (CNS) treatments, clinical capabilities of the hospital, and digital technology to create new therapeutic options. On October 15, Bukwang Pharmaceutical announced that it signed a memorandum of understanding (MOU) with Samsung Medical Center and Bluesignum for the joint development of the software medical device Affectus. Under this agreement, the three parties will collaborate throughout the entire development process of Affectus, including clinical development, product enhancement, regulatory approval, and application in clinical settings. Bukwang Pharmaceutical will contribute its expertise in CNS and commercialization experience, Samsung Medical Center will provide clinical research capabilities, and Bluesignum will offer digital technology and product development expertise. Affectus is a software medical device currently under development, aimed at enhancing social cognitive function in patients with schizophrenia. It is designed to support patients reintegration into daily life and society through digital-based social cognitive training. An exploratory clinical trial is currently underway at Samsung Medical Center. The institutions plan to continue their collaboration to enhance the clinical applicability of Affectus and to develop it into a new treatment option for schizophrenia. Lee Jae-young, CEO of Bukwang Pharmaceutical, stated, We will work together to develop treatment options that benefit patients based on Bukwang Pharmaceuticals expertise in the CNS field. Meanwhile, Bukwang Pharmaceutical became the largest shareholder of Korea Union Pharmaceutical by investing 30 billion won in new shares during its rehabilitation process in May. Recently, Bukwang Pharmaceutical changed the name of the acquired Korea Union Pharmaceutical to Bukwang Unipharma and has begun integrating production systems.* This article has been translated by AI. October 22, 2026 09